Compare Boston Scientific Corporation (BSX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Royal Caribbean Cruises Ltd — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while Royal Caribbean Cruises Ltd trades at $307.9 (market cap $82.15B). The key difference: Boston Scientific Corporation and Royal Caribbean Cruises Ltd are close in size by market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | RCL | |
|---|---|---|
Market Cap | $74.19B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $365.84 |
52-Week Low | $42.63 | $246.71 |
Enterprise Value | $86.27B | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Royal Caribbean (RCL) trades at $309.24, up 0.4% with a bullish technical signal. The company shows strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 vs. $3.98 estimate, and revenue growth accelerating from $8.8B in 2022 to $17.9B in 2025. Net income margin improved to 23.54% while ROE stands at 45.33%. Recent news highlights strong demand and record pricing for 2027 bookings, though geopolitical concerns have slightly tempered European outlook.
RCL presents a compelling growth story with robust earnings momentum and analyst consensus pointing to 11% upside to the $343.09 price target. Key risks include geopolitical impacts on European itineraries, elevated debt levels at $18.47B long-term, and capital-intensive fleet expansion. The stock's premium valuation at P/E 18.97 requires continued execution on growth targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
